Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro.

Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro. Oncol Lett. 2018 Jan;15(1):833-838 Authors: Moriyama G, Tanigawa M, Sakai K, Hirata Y, Kikuchi S, Saito Y, Kyoyama H, Matsuda K, Seike M, Gemma A, Uematsu K Abstract It was previously revealed that Wnt signaling is activated in mesothelioma cells. Although epidermal growth factor receptor (EGFR) is expressed in mesothelioma cells, EGFR-tyrosine kinase inhibitors (TKIs) are not effective for mesothelioma treatment. However, in non-small cell lung cancer, the blocking of Wnt signaling has been identified to enhance the anticancer effect of EGFR-TKIs. To confirm the anticancer effect of blocking Wnt signaling in combination with EGFR-TKI treatment in mesothelioma, the present study evaluated the effect of simultaneous suppression of human dishevelled-3 (Dvl-3) expression with Dvl-3 small interfering RNA (siRNA) and of EGFR inhibition with gefitinib on mesothelioma cell viability. Mesothelioma cell lines with and without β-catenin gene expression were transfected with Dvl-3 siRNA and were cultured with gefitinib, and cell viability, colony formation and cell cycle analyses were performed. Dvl-3 siRNA downregulated the expression of Dvl-3 in mesothelioma cells. The combination of Dvl-3 siRNA with gefitinib acted synergistically to induce concomitant suppression of cell viability and colony formation, suggesting t...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining why each is poised to change the landscape of pat... Author: BeaconMedIC Added: 05/23/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Abstract Pemetrexed (PEM) is a novel and multi-targeted antifolate used as an antineoplastic agent for non-small cell lung cancer (NSCLC) and pleural mesothelioma. Although glucocorticoid was often used with PEM to reduce toxicity during the chemotherapy, it is not clear yet whether glucocorticoid co-administration could affect PEM efficacy in NSCLC. Here we established NSCLC cell lines and examined the effects of dexamethasone (DEX) on PEM sensitivity in vitro and in xenograft models. DEX co-administration reduced chemotherapy sensitivity to PEM in xenograft models. DEX co-administration promoted cell growth and ...
Source: Food and Chemical Toxicology - Category: Food Science Authors: Tags: Food Chem Toxicol Source Type: research
Authors: Leprieur EG, Jablons DM, He B Abstract The Sonic Hedgehog (Shh) pathway is physiologically involved during embryogenesis, but is also activated in several diseases, including solid cancers. Previous studies have demonstrated that the Shh pathway is involved in oncogenesis, tumor progression and chemoresistance in lung cancer and mesothelioma. The Shh pathway is also closely associated with epithelial-mesenchymal transition and cancer stem cells. Recent findings have revealed that a small proportion of lung cancer cells expressed an abnormal full-length Shh protein, associated with cancer stem cell features...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSION: Inter-observer delineation variability has a relevant influence on radiomics analysis and is strongly influenced by tumor type. This leads to a reduced number of suitable imaging features. PMID: 29513054 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Every year, mesothelioma specialists and researchers make strides to advance the standard of care, improve treatment strategies and develop new diagnostic practices. Mesothelioma remains a rare cancer, with an estimated 3,000 people diagnosed each year in the U.S., but the fight to find a cure only grows stronger. And while researchers are busy finding breakthroughs in care, advocates are hard at work campaigning for a ban on asbestos, the main cause of mesothelioma. This was a memorable year on both fronts. Immunotherapy continues to be the hot topic among emerging treatments. Drugs such as pembrolizumab (Keytruda) and ni...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: canada asbestos ban Food and Drug Administration Furthering Asbestos Claims Transparency Act keytruda Medical marijuana mesothelioma mesothelioma vaccine Opdivo Scott Pruitt talcum powder lawsuit yervoy Source Type: news
A leading biopharmaceutical company has halted a once-promising mesothelioma clinical trial involving CRS-207 — a listeria-based cancer vaccine — citing efficacy and financial concerns. The phase II trial was designed to test the effectiveness and safety of CRS-207 when used in combination with pembrolizumab (Keytruda), a drug already proven effective with non-small cell lung cancer. The trial, which began earlier this year, was being conducted at eight prominent cancer centers across the United States. It was funded by Aduro Biotech Inc., based in Berkley, California. “This was not the news everyone had ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Abramson Cancer Center Aduro Biotech Cleveland Clinic CRS-207 H. Lee Moffitt Cancer Center keytruda Listeria virus Mayo Clinic mesothelioma immunotherapy Natalie Sacks NIH National Cancer Institute pembrolizumab Perlmutter Cancer C Source Type: news
Pemetrexed, a multitargeted antifolate cytotoxic agent, is currently used primarily in combination with cisplatin for metastatic non-small cell lung cancer and for malignant mesothelioma. Acute renal toxicity ...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Case report Source Type: research
AbstractThis review considers the “promise” of exploiting the proton-coupled folate transporter (PCFT) for selective therapeutic targeting of cancer. PCFT was discovered in 2006 and was identified as the principal folate transporter involved in the intestinal absorption of dietary folates. The recognition that PCFT was highly ex pressed in many tumors stimulated substantial interest in using PCFT for cytotoxic drug targeting, taking advantage of its high level transport activity under the acidic pH conditions that characterize many tumors. For pemetrexed, among the best PCFT substrates, transport by PCFT establ...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results. The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year. Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street. &ld...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Genetics | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Study